SAILIFE · Healthcare · Diagnostics & Research
Composite scorecard: 57/100 — Quality 70 · Valuation 0 · Growth 71 · Momentum 100
| Share price | ₹1,297.00 |
| Market cap | ₹21,126 Cr |
| P/E ratio | 62.9 |
| P/B ratio | 9.2 |
| ROE | 22.8% |
| ROCE | 12.5% |
| Book value | ₹108.17 |
| Year | Sales | Net profit | OPM |
|---|---|---|---|
| 2026 | ₹2,192 Cr | ₹349 Cr | 29.0% |
| 2025 | ₹1,695 Cr | ₹170 Cr | 24.0% |
| 2024 | ₹1,465 Cr | ₹83 Cr | 20.0% |
| 2023 | ₹1,217 Cr | ₹10 Cr | 14.0% |
| 2022 | ₹870 Cr | ₹6 Cr | 15.0% |
Sai Life Sciences Limited operates as a contract research, development, and manufacturing organization (CRDMO) in India and internationally. It provides medicinal chemistry, pharmacokinetics, manufacturing, and contract development services. The company was formerly known as SAI Advantium Pharma Limited and changed its name to Sai Life Sciences Limited in July 2006. Sai Life Sciences Limited was incorporated in 1999 and is based in Hyderabad, India.